Viking Therapeutics Stock Plunges on Clinical Trial Concerns

Viking Therapeutics is experiencing the downside of its ambitious growth strategy. Recent clinical developments have tempered investor enthusiasm for the biotech firm, sending shares downward despite previous monthly gains. The primary concern stems from high discontinuation rates observed in trials for the company’s oral weight loss medication.

The company’s latest quarterly report reveals significant financial pressure. During the second quarter of 2025, research and development expenditures surged to $60.2 million—more than double the $23.8 million recorded during the same period last year.

This explosive cost growth has dramatically impacted the bottom line. Viking’s net loss widened substantially to $65.6 million, compared to $22.3 million in the prior year period. While the company maintains solid cash reserves,... Read more...